Post-market Study of the TOPS™ System
TOPS
A Study to Evaluate the Safety and Effectiveness of the TOPS System
1 other identifier
interventional
10
1 country
1
Brief Summary
The study is being conducted to evaluate look the TOPS System when used in patients with degenerative spondylolisthesis and lumbar spinal stenosis who would normally be candidates for spinal fusion.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started May 2014
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 8, 2013
CompletedFirst Posted
Study publicly available on registry
September 2, 2013
CompletedStudy Start
First participant enrolled
May 1, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2016
CompletedApril 18, 2016
April 1, 2016
2.6 years
March 8, 2013
April 14, 2016
Conditions
Outcome Measures
Primary Outcomes (1)
Improvement in ODI and improvement in VAS leg score
Composite endpoint - Subjects who exhibit a reduction of 15 percent in their Oswestry Disability Index (ODI) score compared to their preoperative ODI score AND a reduction of at least 20mm (20% improvement) in either of their VAS Leg Score will be considered a success.
24 months post implantation
Secondary Outcomes (4)
Average improvement in back and leg visual analog scales (VAS)
24 months post implantation
ZCQ Scores
24 months post implantation
Quality of life (SF-36)
24 months post implantation
Maintenance or improvement in neurological symptoms
24 months post implantation
Study Arms (1)
TOPS System
OTHERPost Marketing Study
Interventions
Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level.
Eligibility Criteria
You may qualify if:
- Age 40-85 years old;
- One or both of the following at a single level from L3 to L5; (1) symptomatic monosegmental lumbar spinal stenosis or facet arthrosis, (2) degenerative spondylolisthesis up to and including grade 1.
- At least three (3) months of failed, conservative treatment prior to surgery (unless deemed inadvisable due to progressive motor weakness or other evidence of rapidly deteriorating condition) including the use of anti-inflammatory medications at maximum specified dosage, administration of epidural/facet injections, rest, heat, electrotherapy and/or physical therapy;
- Narrowing of the lumbar spinal canal (central and/or foramenal) classified as moderate to severe using CT scans/MRI;
- VAS leg pain of at least 40/100;
- Oswestry Disability Index score of at least 40/100;
- Lower back pain or sciatica with or without spinal claudication and
- Psychosocially, mentally and physically able to fully comply with the clinical protocol and willing to adhere to follow-up schedule and requirements.
You may not qualify if:
- Primary diagnosis of discogenic back pain at the TOPS System level;
- Back or non-radicular leg pain of unknown etiology at the index level;
- Lytic spondylolisthesis at the index level;
- Known allergy to titanium and/or polyurethane;
- Supplemental interbody support required (e.g., bone graft, spacers, VBRs, or fusion cages) at the index level;
- Clinically compromised vertebral bodies at the affected level(s) due to any traumatic, neoplastic, metabolic or infectious pathology;
- Deformity of the spine that would compromise the implant, e.g. scoliosis of greater than ten (10) degrees;
- Morbid obesity defined as a body mass index \> 40 or a weight more than 100 lbs. over ideal body weight;
- DEXA bone density measured T score equal to or lower than - 2.0;
- Paget's disease, osteomalacia, osteogenesis imperfecta, thyroid and/or parathyroid gland disorder and/or any other metabolic bone disease;
- Active infection;
- AIDS, HIV, or active hepatitis;
- Rheumatoid arthritis or other autoimmune disease;
- Tuberculosis active or in the past 3 years;
- Active malignancy: unless treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years;
- +13 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Premia Spinelead
Study Sites (1)
University Hospital Southampton NHS Foundation Trust
Southampton, Southampton, SO16 6YD, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
John Fowler, MD
University Southampton Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 8, 2013
First Posted
September 2, 2013
Study Start
May 1, 2014
Primary Completion
December 1, 2016
Study Completion
December 1, 2016
Last Updated
April 18, 2016
Record last verified: 2016-04